Bicara Therapeutics BCAX Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| —— | $63.6M— | ||
| $30.51M+62.5% | $18.77M— | ||
| $155.6M+88.9% | $82.39M— | ||
| -$155.6M-88.9% | -$82.39M— | ||
| $17.87M+22.6% | $14.58M— | ||
| -$137.73M-103% | -$67.81M— | ||
| $217K+16.0% | $187K— | ||
| -$137.95M-103% | -$68M-30.8% | ||
| -$2.53— | —— | ||
| -$155.5M-88.9% | -$82.33M— | ||
| -$155.6M-88.9% | -$82.39M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Bicara Therapeutics profitable?
- Bicara Therapeutics is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months.
- What is Bicara Therapeutics's earnings per share?
- Bicara Therapeutics's diluted EPS over the trailing twelve months is $-2.78.
- Where does Bicara Therapeutics's income statement data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.